GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
